Arvinas to Participate in Upcoming Investor Conferences
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company specializing in targeted protein degradation, has announced its participation in two upcoming investor conferences:
- The Wells Fargo Healthcare Conference on September 5, 2024, featuring a fireside chat with Ian Taylor, Ph.D., President of R&D, and Randy Teel, Ph.D., Chief Business Officer.
- The Cantor Global Healthcare Conference on September 19, 2024, with Noah Berkowitz, MD, Ph.D., Chief Medical Officer, and Andrew Saik, Chief Financial Officer, participating in a fireside chat.
Both presentations will be available via live audio webcast on the company's website and through provided links. This engagement with investors highlights Arvinas' commitment to transparency and shareholder communication.
Arvinas, Inc. (Nasdaq: ARVN), un'azienda biotecnologica in fase clinica specializzata nella degradazione mirata delle proteine, ha annunciato la sua partecipazione a due prossime conferenze per investitori:
- La Wells Fargo Healthcare Conference il 5 settembre 2024, con un'intervista a colloquio con Ian Taylor, Ph.D., Presidente della R&D, e Randy Teel, Ph.D., Direttore Commerciale.
- La Cantor Global Healthcare Conference il 19 settembre 2024, con Noah Berkowitz, MD, Ph.D., Direttore Medico, e Andrew Saik, Direttore Finanziario, che parteciperanno a un'intervista a colloquio.
Entrambe le presentazioni saranno disponibili tramite webcast audio in diretta sul sito web dell'azienda e attraverso i link forniti. Questo coinvolgimento con gli investitori evidenzia l'impegno di Arvinas per la trasparenza e la comunicazione con gli azionisti.
Arvinas, Inc. (Nasdaq: ARVN), una empresa de biotecnología en etapa clínica especializada en la degradación dirigida de proteínas, ha anunciado su participación en dos próximas conferencias para inversores:
- La Wells Fargo Healthcare Conference el 5 de septiembre de 2024, que contará con una charla junto a la chimenea con Ian Taylor, Ph.D., Presidente de I&D, y Randy Teel, Ph.D., Director de Negocios.
- La Cantor Global Healthcare Conference el 19 de septiembre de 2024, donde participarán Noah Berkowitz, MD, Ph.D., Director Médico, y Andrew Saik, Director Financiero, en una charla junto a la chimenea.
Ambas presentaciones estarán disponibles a través de un webcast de audio en vivo en el sitio web de la empresa y a través de los enlaces proporcionados. Este compromiso con los inversores destaca el compromiso de Arvinas con la transparencia y la comunicación con los accionistas.
아르비나스 주식회사 (Nasdaq: ARVN)는 표적 단백질 분해를 전문으로 하는 임상 단계의 생명공학 회사로서, 두 개의 다가오는 투자자 컨퍼런스에 참여한다고 발표했습니다:
- 2024년 9월 5일, 웰스 파고 헬스케어 컨퍼런스에서 R&D 사장인 이안 테일러 박사와 사업 담당 책임자인 랜디 틸 박사와의 화상 대화가 진행됩니다.
- 2024년 9월 19일, 칸토 글로벌 헬스케어 컨퍼런스에서 의무 담당 책임자 노아 버코위츠 박사와 재무 책임자 앤드류 사이크가 화상 대화에 참여합니다.
두 발표 모두 회사 웹사이트와 제공된 링크를 통해 실시간 오디오 웹캐스트로 제공될 예정입니다. 투자자와의 이러한 상호작용은 아르비나스가 투명성과 주주 소통에 대한 의지를 강조합니다.
Arvinas, Inc. (Nasdaq: ARVN), une entreprise biopharmaceutique en phase clinique spécialisée dans la dégradation ciblée des protéines, a annoncé sa participation à deux conférences pour investisseurs à venir :
- La Wells Fargo Healthcare Conference le 5 septembre 2024, avec une discussion en tête-à-tête entre Ian Taylor, Ph.D., Président de la R&D, et Randy Teel, Ph.D., Directeur des affaires.
- La Cantor Global Healthcare Conference le 19 septembre 2024, avec Noah Berkowitz, MD, Ph.D., Directeur médical, et Andrew Saik, Directeur financier, participant à une discussion en tête-à-tête.
Les deux présentations seront disponibles via webcast audio en direct sur le site de l'entreprise et par le biais des liens fournis. Cet engagement envers les investisseurs met en avant l'engagement de Arvinas pour la transparence et la communication avec les actionnaires.
Arvinas, Inc. (Nasdaq: ARVN), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die zielgerichtete Proteindegradation spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben:
- Die Wells Fargo Healthcare Conference am 5. September 2024, mit einem Fireside-Chat mit Ian Taylor, Ph.D., Präsident der F&E, und Randy Teel, Ph.D., Chief Business Officer.
- Die Cantor Global Healthcare Conference am 19. September 2024, bei der Noah Berkowitz, MD, Ph.D., Chief Medical Officer, und Andrew Saik, Chief Financial Officer, an einem Fireside-Chat teilnehmen.
Beide Präsentationen werden über einen Live-Audio-Webcast auf der Unternehmenswebsite und über die bereitgestellten Links verfügbar sein. Dieses Engagement mit Investoren unterstreicht Arvinas' Engagement für Transparenz und Kommunikation mit Aktionären.
- None.
- None.
NEW HAVEN, Conn., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences:
- Wells Fargo Healthcare Conference on Thursday, September 5, 2024.
- Ian Taylor, Ph.D., President, R&D, and Randy Teel, Ph.D., Chief Business Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.
- Ian Taylor, Ph.D., President, R&D, and Randy Teel, Ph.D., Chief Business Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.
- Cantor Global Healthcare Conference on Thursday, September 19, 2024.
- Noah Berkowitz, MD, Ph.D. Chief Medical Officer, and Andrew Saik, Chief Financial Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC® (PROteolysis Targeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
FAQ
When is Arvinas (ARVN) participating in the Wells Fargo Healthcare Conference?
Who will represent Arvinas (ARVN) at the Cantor Global Healthcare Conference?
Where can investors watch the live webcast of Arvinas' (ARVN) presentations?
What type of company is Arvinas (ARVN)?
